Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
98 EUR | -1.01% |
|
-.--% | +2.08% |
08:13am | Roche reports positive early results in obesity drug trial | RE |
Jul. 16 | Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly | MT |
Sales 2024 * | 42.99B 39.42B | Sales 2025 * | 52.8B 48.43B | Capitalization | 848B 778B |
---|---|---|---|---|---|
Net income 2024 * | 11.93B 10.94B | Net income 2025 * | 16.68B 15.3B | EV / Sales 2024 * | 20.2 x |
Net Debt 2024 * | 20.24B 18.56B | Net Debt 2025 * | 16.14B 14.8B | EV / Sales 2025 * | 16.4 x |
P/E ratio 2024 * |
70.4
x | P/E ratio 2025 * |
50.3
x | Employees | - |
Yield 2024 * |
0.55% | Yield 2025 * |
0.64% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 day | -1.01% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 04-12-31 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.95% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+5.89% | 234B | |
+16.53% | 225B | |
+15.67% | 179B | |
+2.47% | 167B | |
+2.41% | 125B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock